Mantle Cell Lymphoma – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Thu, 09 Mar 2023 11:31:47 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Mantle Cell Lymphoma – VJRegenMed https://mirror.vjregenmed.com 32 32 Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL https://mirror.vjregenmed.com/video/kdyh3c3upiq-safety-and-efficacy-of-lv20-19-car-t-therapy-in-richters-transformation-and-rr-mcl/ Thu, 09 Mar 2023 11:31:47 +0000 https://mirror.vjregenmed.com/video/kdyh3c3upiq-safety-and-efficacy-of-lv20-19-car-t-therapy-in-richters-transformation-and-rr-mcl/ Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the results of two studies evaluating the LV20.19 CAR-T product in patients with Richter’s transformation and in patients with heavily pretreated mantle cell lymphoma (MCL; NCT04186520). Out of the six patients with Richter’s transformation who were evaluated, four achieved a durable remission and the overall response rate (ORR) was 100%. Patients presented a unique toxicity profile, with a high incidence of hemophagocytic lymphohistiocytosis (HLH)-like toxicity. In MCL, eight of the 14 patients in the study met the primary endpoint, and the ORR at day 90 was 100%. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

]]> LMY-920 in non-Hodgkin lymphoma https://mirror.vjregenmed.com/video/jrdkliwleru-lmy-920-in-non-hodgkin-lymphoma/ Mon, 14 Feb 2022 17:40:19 +0000 http://13.40.107.223/video/jrdkliwleru-lmy-920-in-non-hodgkin-lymphoma/ Patients with B-cell non-Hodgkin lymphoma (NHL) can progress on current anti-CD19 chimeric antigen receptor (CAR) T-cell therapies due to antigen escape. Jeff Liter, MBA, Luminary Therapeutics, Minneapolis, MN, provides an overview of LMY-920, a B-cell activating factor (BAFF)-directed CAR-T therapy, which consists of three different antigens on the CAR T-cell. The three markers prevents antigen escape and the therapy additionally contains no foreign linkers, reducing immunogenicity. An Investigational New Drug Application (IND) will be imminently filed for LMY-920, with the therapy aiming to target NHL and mantle cell lymphoma (MCL). This interview took place at Advanced Therapies Week 2022.

]]> The future of CAR T-cell therapy in lymphoma https://mirror.vjregenmed.com/video/5ifwhbgg4le-the-future-of-car-t-cell-therapy-in-lymphoma/ Fri, 26 Feb 2021 14:08:21 +0000 http://13.40.107.223/video/5ifwhbgg4le-the-future-of-car-t-cell-therapy-in-lymphoma/ Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the future directions of CAR T-cell therapy in lymphoma. The availability of CAR-T has modified the treatment algorithm for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Indications for CAR T-cell therapy will likely expand to earlier lines of treatment and other lymphomas. Dr Sureda is looking forward to the data from three Phase III clinical trials comparing CAR T-cell therapies with autologous stem cell transplantation in patients with primary refractory disease. Additionally, strategies to improve efficacy and toxicity are certainly desirable. This interview took place during the 3rd European CAR T-cell Meeting.

]]>